Nuveen Asset Management, LLC - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 67 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$12,958,823
-34.0%
373,992
-44.9%
0.00%
-33.3%
Q1 2024$19,620,355
+180.2%
678,201
+122.1%
0.01%
+200.0%
Q4 2023$7,003,258
-21.7%
305,419
-43.0%
0.00%
-33.3%
Q3 2023$8,940,881
-65.4%
536,024
-42.7%
0.00%
-66.7%
Q2 2023$25,851,242
+135566.4%
935,961
+13.0%
0.01%
+28.6%
Q1 2023$19,055
+384.1%
828,471
+129.7%
0.01%
+250.0%
Q4 2022$3,936
-99.9%
360,714
+6.5%
0.00%
+100.0%
Q3 2022$2,854,000
+6.7%
338,544
+0.2%
0.00%0.0%
Q2 2022$2,674,000
+13.7%
337,972
+11.1%
0.00%0.0%
Q1 2022$2,351,000
+26.8%
304,112
+26.8%
0.00%0.0%
Q4 2021$1,854,000
+47.0%
239,929
+47.1%
0.00%
Q3 2021$1,261,000
-1.9%
163,086
-1.9%
0.00%
Q2 2021$1,286,000
+15.0%
166,325
+14.9%
0.00%
Q1 2021$1,118,000
+28.5%
144,700
+28.5%
0.00%
Q4 2020$870,000
-0.7%
112,571
-0.6%
0.00%
Q3 2020$876,000
+25.0%
113,297
+24.8%
0.00%
Q2 2020$701,000
+0.1%
90,772
-8.4%
0.00%
Q1 2020$700,000
-48.9%
99,073
-49.0%
0.00%
-100.0%
Q4 2019$1,370,000
-24.2%
194,437
+29.2%
0.00%0.0%
Q3 2019$1,808,000
+284.7%
150,531
+287.2%
0.00%
Q2 2019$470,00038,8750.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Johnson & Johnson Innovation - JJDC, Inc. 2,449,183$43,253,0008.50%
BVF INC/IL 2,367,288$41,806,0002.58%
RTW INVESTMENTS, LP 3,383,208$59,747,0001.68%
Novo Holdings A/S 824,169$14,555,0000.94%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,013,495$17,898,0000.52%
Sofinnova Investments, Inc. 326,064$5,758,0000.36%
FARALLON CAPITAL MANAGEMENT LLC 2,500,000$44,150,0000.35%
Virtus ETF Advisers LLC 21,639$382,0000.18%
Baker Brothers Advisors 1,911,446$33,756,0000.15%
King Wealth Management Group 22,000$389,0000.11%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders